Lung Cancer Response to Gefitinib, Then Erlotinib, Then Gefitinib Again
نویسندگان
چکیده
منابع مشابه
Predicting Tumor Responses to Gefitinib and Erlotinib
0002 Streptococcus pneumoniae is a common bacterium that is present in the nasopharynx of many children and some adults, where it causes no harm to its carrier but can be transmitted to others. If it moves beyond the nasopharynx, however, it can cause ear infections or invasive disease, such as pneumonia or meningitis. Invasive disease from this organism occurs especially in children, the elder...
متن کاملSuccessful Erlotinib Treatment for a Patient with Gefitinib-Related Hepatotoxicity and Lung Adenocarcinoma Refractory to Intermittently Administered Gefitinib
A 73-year-old Japanese man was histologically diagnosed with lung adenocarcinoma harboring an exon 19 deletion in the epidermal growth factor receptor. The patient was treated with gefitinib for 6 weeks until he developed substantially elevated hepatic enzyme levels that resulted in the discontinuation of gefitinib. Gefitinib was reintroduced with an intermittent treatment schedule after the tr...
متن کاملErlotinib Achieved Partial Response in a Non-Small Cell Lung Cancer Patient with Gefitinib-Induced Interstitial Lung Disease
Interstitial lung disease (ILD) induced by epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib and erlotinib, is a rare but fatal complication of TKI treatment. Transfer to chemotherapy or continuation with TKI of reduced dose are alternative treatment strategies. We report a case of severe ILD in a non-small cell lung cancer patient treated with gefitinib...
متن کاملPhase II study of gefitinib readministration in patients with advanced non-small cell lung cancer and previous response to gefitinib.
OBJECTIVE Salvage treatment for acquired resistance to gefitinib has yet to be developed. We conducted the first prospective phase II study of gefitinib readministration in previous gefitinib responders. METHODS Gefitinib (250 mg/day) was readministered to patients with advanced/metastatic non-small cell lung cancer who had achieved objective response to initial gefitinib and subsequently rec...
متن کاملGefitinib in Non Small Cell Lung Cancer
Gefitinib is an oral, reversible, tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) that plays a key role in the biology of non small cell lung cancer (NSCLC). Phase I studies indicated that the recommended dose of gefitinib was 250 mg/day. Rash, diarrhea, and nausea were the most common adverse events. The positive results obtained in early phase 2 clinical trials with gefit...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Thoracic Oncology
سال: 2008
ISSN: 1556-0864
DOI: 10.1097/jto.0b013e318183afb0